Entropy Neurodynamics (ASX:ENP) has marked a significant clinical milestone, successfully administering the first dose of its proprietary psilocin formulation, TRP-8803, in a trial targeting binge eating disorder.

CLINUVEL Pharmaceuticals (ASX:CUV) has taken a significant step toward expanding its product portfolio, confirming it is planning to lodge a European regulatory submission for its second pharmaceutical product, NEURACTHEL Instant, by mid-2026.

Chimeric Therapeutics (ASX:CHM) has reassured investors of its strategic direction and clinical momentum, announcing a forthcoming refresh of its board and reaffirming backing from major shareholders following its Annual General Meeting held on 25 November.

Cartherics has announced a significant leadership transition, appointing biotechnology executive and company co-founder Dr Ian Nisbet as Chief Executive Officer as the Melbourne-based cell therapy developer prepares for its next phase of growth.

Melbourne is putting its biomedical and health innovation ecosystem on display as delegates from across Australia and overseas gather in the city for the National Health and Innovation Precincts Summit, the first time the annual event has been hosted in Victoria.

Tetratherix (ASX:TTX) has announced a significant step forward for its US-based joint venture BioOptix, with the ophthalmic biomaterials company signing a development agreement with global eye-care leader Alcon Research.

The agreement brings together Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s CD19-directed autologous CAR-T therapy, Carteyva, in a program that spans preclinical studies through to a Phase 1 investigator-initiated clinical trial in China.

Neurizon Therapeutics (ASX:NUZ) Chair Sergio Duchini has told shareholders the company is entering a decisive phase in its mission to bring new treatments to patients with neurodegenerative diseases, describing the past year as one of disciplined execution, strengthened governance, and meaningful scientific progress.

Syntara (ASX:SNT) has taken a significant step forward in the development of its next-generation topical anti-fibrotic therapy, announcing that its lead pan-lysyl oxidase inhibitor, SNT-9465, has completed a Phase 1a clinical trial and will now progress into a Phase 1b study in patients with hypertrophic scars.

AdAlta’s (ASX:1AD) Chair has told shareholders the company has reached a pivotal point in its strategic transformation, describing 2025 as the year the business fully committed to its 'East to West' cellular immunotherapy model and positioned itself to unlock significant near-term value across its pipeline.

Proteomics International (ASX:PIQ) has secured a significant milestone in its push into the US healthcare market, with Medicare authorities setting a national reimbursement price of US$390.75 for its PromarkerD test, a predictive diagnostic for diabetic kidney disease.

Recce Pharmaceuticals (ASX:RCE) has announced promising new preclinical results demonstrating that its lead anti-infective, RECCE 327, delivered via inhalation, can significantly reduce bacterial burden in a validated mouse model of hospital- and ventilator-acquired pneumonia.

Race Oncology (ASX:RAC) has received human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial evaluating RC220, its next-generation formulation of bisantrene, in combination with AstraZeneca's TAGRISSO (osimertinib) for patients with EGFR-mutated non-small cell lung cancer.

Race Oncology (ASX:RAC) has described the past year as one of the most defining in its history, marked by scientific progress, strengthened clinical capability and decisive steps toward realising the full potential of its lead asset, RC220.

A groundbreaking new biologic targeting interferon-driven autoimmune diseases has earned Professor Claudia Nold the top prize at this year’s Early-Stage Innovation Forum, held during the AusBiotech International Conference 2025 in Melbourne.

Syntara (ASX:SNT) has launched a new Phase 2 clinical study that could shift the treatment landscape for Australians living with transfusion-dependent Myelodysplastic Syndromes, a rare blood cancer associated with bone marrow failure and limited therapeutic options.